Today the nuclear medicine is an advanced way of oncologic, neurologic and cardiac diseases diagnosis and treatment, while the nuclear medicine development is impossible without radiopharmaceuticals. ...
The new WHO and IAEA guidelines are intended to provide a general overview of GMP (Good Manufacturing Practice) requirements for radiopharmaceuticals. While the basics of GMP are presented in the gene...
The Israeli Isotopia Company, in collaboration with Prof. Rachela Popovtzer of Bar-Ilan University's Faculty of Engineering, is conducting a joint study to develop a radioactive marker for the detection of cancer.
A Nuclear Medicine Center may be soon established in the Ural region as a result of efforts by the specialists of the Institute of Reactor Materials (an enterprise of Scientific Division of Rosatom State Corporation).
Endocyte and ITM Isotopen Technologien München AG (ITM) announced that ITM´s subsidiary and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta.
Russia’s first new generation cyclotron (accelerator of particles) intended for manufacturing pharmaceuticals for cancer diagnosis was installed at Dr. Berezin Medical Institute (MIBS) in St. Petersburg.
Telix Pharmaceuticals announced a research partnership with the French National Institute of Health and Medical Research and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic”.
Actinium Pharmaceuticals entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.